TIER-1 ENDOSURE Test
Empowering You to Diagnose Endometriosis at First Patient Visit
TIER-1 DIAGNOSTIC SUPPORT
- Highly accurate
- Testing takes less than an hour
- Provides instant results
- Detects all disease stages
PATIENT CENTRED EXPERIENCE
- For all ages, premenarche to post menopause
- Painless & trauma informed
- Minimal patient preparation
- Patients remain fully clothed during test
CLINICAL FIT
- Manufacturer Certified Training for your staff
- No special equipment required beyond ENDOSURE System
- No biological sample collection or disposal required
- Auto-diagnostic & self calibrating
Clinical evidence for practitioners who suspect endometriosis
GIMA Biomarker of Endometriosis
ENDOSURE test uses an electroviscerography system (EVG), an analytical instrument that collects Gastrointestinal Myoelectrical Activity (GIMA) signals from the abdomen through dry electrodes. EVG measures GIMA patterns unique to endometriosis sufferers.
Common indications for TIER-1 testing:
- Dysmenorrhea and/or chronic pelvic pain
- Dysuria, dyschezia, dyspareunia
- IBS /GI/Bloating symptoms
- Anxiety and/or depression
- Infertility and/or miscarriage
Information for Providers
Patient Information
Talk to Us
Mechanism of Action of Endometriosis effect
The Science
Tier 1 Diagnostic Test for Endometriosis – results in 30 minutes
How it works
Electroviscerography system (EVG) is an analytical instrument that non-invasively collects myoelectrical activity signals from the gastrointestinal tract (GIMA).
The ENDOSURE test records the GIMA pattern. This data is analyzed, then compared to the GIMA biomarker of endometriosis, a known digital “fingerprint” of people who suffer from endometriosis.2,3,4,5
The near-instant results of this pain-free diagnostic test support your diagnosis of endometriosis and expedites the process for treatment and management of the disease.
What Clinicians are Saying
“We’ve not seen any real movement in the treatments and the diagnosis of endometriosis for like two decades and now it’s all seems to be coming together. It’s a combination of the ENDOSURE test and the new drugs, which is going to change the management for many of these young women.”
- Dr. David Griffiths, Consultant Gynaecologist MB ChB, FRCOG
“ Until now we haven’t had a very good, simple, easy, quick, inexpensive screening test for endometriosis. Until now the only way to diagnose endometriosis definitively has been with a surgical procedure. Still to this day, the average time from onset of symptoms to diagnosis is anywhere from 7 to 12 years. And the average woman who has these symptoms sees anywhere from seven to 10 different doctors before they get a diagnosis. We have the potential to crack that nut.
Larry Glazerman, MD, MBA
“If patients understand why they’re experiencing symptoms, it helps them cope, reduces stress, and creates closure so they can move forward with appropriate treatment. ENDOSURE testing provides that clarity in minutes rather than years.”
-Dr. Sarah Roth, ND
International Institutions Conducting Validating Research
Abstract Presentation, IIRRM Congress 2025, Zagreb, Croatia
LAtest Research
Abstract Title: Gastrointestinal Myoelectrical Activity (GIMA) Biomarker Accurately Determines Presence of Absence of Endometriosis
Presented by Maria Bizecki-Porcellato, BSP, ACPR, CFCP, CFCPh.
Confirming research for the ENDOSURE test was presented as an Abstract in Zagreb, Croatia at the 2025 RRM Congress. This research was significant, as the 340 patient set validated the ENDOSURE test used in a real world experience. Key findings include a sensitivity of 95%, a specificity of 86%, and a diagnostic accuracy of 92%.
Oral Abstract Presentation, AAGL 2025, Vancouver, BC, Canada
Validating Research
Abstract Title: Defining the role of the gastrointestinal myoelectrical activity (GIMA) biomarker in the diagnosis of endometriosis
Authors: P Tanos, F Donders, A Massaro, S Philippe, S Karampelas
Findings: CHU Bruggman, Brussels, validated GIMA v. MRI (35 patients), TV-US (45 patients) and laparoscopy (12 patients) using #Enzian classification. Sensitivity 100%, specificity of 5% (no benign cohort), diagnostic accuracy of 96% in detecting both deep and superficial endometriosis (preliminary data, May 2025). Notably, GIMA biomarkers identified superficial endometriosis in cases missed by conventional imaging. Additionally, 60% of patients preferred ENDOSURE over TV-US.
Oral Abstract Presentation, AAGL 2025, Vancouver, BC, Canada
Validating Research
Oral Presentation #2, AAGL 2025, Vancouver, BC, Canada
Abstract Title: Non-Invasive Electroviscerography for the Diagnosis of Endometriosis: A Prospective Pilot Study
Authors: Marina P Andres, MD , Ana Clara P Servidoni , Ana Luiza B Luduwig , Lara L Passos , Mariana M Brunoro and Mauricio S Abrao, MD
Findings: Compared to laparoscopy (n=13) of 43 women, EVG showed sensitivity 100%, specificity 0% (no benign cohort), accuracy 92.31%.
Published Research:
1. Mathias JR, Franklin R, Quast DC, Fraga N, Loftin CA, Yates L, Harrison V. Relation of endometriosis and neuromuscular disease of the gastrointestinal tract: new insights. Fertil Steril. 1998 Jul;70(1):81-8.
2, Noar M, Mathias J, Kolatkar A. Gastrointestinal Myoelectrical Activity (GIMA) Biomarker for Noninvasive Diagnosis of Endometriosis. J Clin Med. 2024;13(10):2866. Published 2024 May 13. doi:10.3390/jcm13102866
3. AI-Derived Threshold Score of Intraabdominal Myoelectrical Activity Predicts Presence and Stage of Endometriosis with 100% Accuracy, Noar, M., Journal of Minimally Invasive Gynecology, Volume 29, Issue 11, S4 – S5. DOI: 10.1016/j.jmig.2022.09.026
4. Mark Noar, John Mathias, Ajit Kolatkar. Validation of New GIMA Biomarker Signature of Endometriosis – Interim Data: Research Article. Advance. August 26, 2024. DOI: 10.22541/au.172469630.08159498/v1
5. Tanos P, Donders F, Massaro A, Philippe S, Karampelas S. Defining the role of the gastrointestinal myoelectrical activity (GIMA) biomarker in the diagnosis of endometriosis. J Minim Invasive Gynecol. 2025;32(11)(suppl):S23. doi:10.1016/j.jmig.2025.09.027
